BioIVT Joins Platform to Help Improve Drug Discovery Success Rates
BioIVT has announced that it has joined the Medicines Discovery Catapult’s Discovery Services Platform, which is aimed at supporting drug discovery within the United Kingdom.
BioIVT has announced in a Sep. 24, 2019 press release that it has joined the Medicines Discovery Catapult’s Discovery Services Platform, which is aimed at supporting drug discovery within the United Kingdom.
As part of the platform, BioIVT will partner up with other service providers in the goal of progressing preclinical drug discovery and increase success rates. BioIVT’s PHASEZERO research services team will be used to provide support in the generation of human tissue-based target validation data as well as the characterization of novel therapeutics.
“BioIVT is dedicated to supporting the research community by providing expertise in human tissue-based approaches that deliver target and biomarker validation data and by developing fit-for-purpose assays that enable characterization of novel therapeutics to accelerate drug discovery and development,” said Amanda Woodrooffe, vice-president and general manager at BioIVT UK, in the press release. “We are delighted to join Medicines Discovery Catapult’s Discovery Services Platform and be able to provide our expertise, access to ethically-sourced human biospecimens, and innovative approaches to support UK enterprises.”
Source: BioIVT
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
